

42. A pharmaceutical composition comprising the β -crystal form of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phey]benzamide and a pharmaceutically acceptable carrier.

43. A pharmaceutical composition comprising the α -crystal form of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phey]benzamide and a pharmaceutically acceptable carrier.

STATUS OF THE CLAIMS

Claims 13-15 were pending.

Claims 13-15 have been deleted.

Claims 16-43 have been added and are presented for consideration.

REMARKS

Applicants have added the above claims to better define Applicants invention. Support for the indications identified in the added claims can be found throughout the specification but particularly on page 12 thereof. Support for 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phey]benzamide in free form or in pharmaceutically acceptable salt form can be found throughout the specification but particularly on page 16, paragraph 3 thereof.

In view of the foregoing, Applicant submits the Application is now in condition for allowance and respectfully requests early notice to that effect.

Respectfully submitted,



Gregory D. Ferraro
Attorney for Applicants
Reg. No. 36,134

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6923

Date: January 8, 2002